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Summary
Background: Primary health care providers are expected to be
directly involved in the genetic testing for cancer susceptibility.
This study assessed physicians' knowledge, attitude and per-
ception of their role towards testing for hereditary breast-
ovarian cancer.
Design: A mail-in survey was sent to all general practi-
tioners, internists, obstetrician-gynecologists and oncologists
in private practice in Geneva county, Switzerland. Questions
included socio-demographic variables, knowledge about he-
reditary breast-ovarian cancer, attitude towards testing and
assessment of their role in the pre- and post-test procedure.
Results: Two hundred fifty-nine (65%) of four hundred
questionnaires were returned of which two hundred forty-three
(61%) were analysed. Response rates were similar between
specialties; women answered more frequently. The majority of
the respondents (87%) approved of genetic susceptibility test-
ing. The most common objection to testing was the absence of
approved strategies for the prevention and detection of early
breast cancer. Most physicians felt they had an active part to
play in the pre-test procedure, the disclosure of results, and
especially the consultants' long-term care and support (99%).
Physicians correctly answered a third (32%) of the knowledge
questions. The abstention rate for individual items ranged from
13% to 60%. Scores varied by specialty. Oncologists were more
knowledgeable than gynecologists, internists and general prac-
titioners.
Conclusions: The majority of the primary care physicians in
this study have a favourable attitude and are ready to play a
prominent role in genetic counseling and testing for breast-
ovarian cancer predisposition. Defective knowledge scores,
however, underline the need for targeted educational pro-
grams.
Key words: attitudes, breast neoplasms, genetic predisposition
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Introduction
The characterization of the BRCA1 and BRCA2 genes
[1-3] represents a major advance in the field of oncology.
It offers the opportunity to identify asymptomatic car-
riers who are at risk of developing breast and/or ovarian
cancer. It also raises complex medical, social, ethical
and psychological issues. Primary care physicians will
be directly involved as genetic testing becomes widely
available [4-7]. Interest among the population is likely
to be strong [8-10] and individuals will solicitate their
physicians for information and testing. Many questions
have to be addressed [11-13]: the potential limitations,
risks and benefits of testing, the options for medical
surveillance as well as confidentiality issues. Familial
cancer risk must be evaluated and counseling provided
accordingly. It means a departure from the traditional
medical consultation. Information is given about proba-
bilities to develop a disease. It implies a non-directive
attitude and a special attention to the emotional needs
and moral values of individuals so as to help them make
an informed decision. Physicians are also expected to
provide ongoing medical care and support to the con-
sultants. Several potential barriers to the integration of
genetic counseling into clinical practice have been rec-
ognized: the acquisition of specific knowledge [14-16],
the handling of probabilistic data [17], the low tolerance
to uncertainty [18] and the time and costs constraints
[19-21]. Two studies [22, 23] exploring general practi-
tioners' attitudes towards genetic testing for Huntington
disease show that most respondents approve of testing.
In the Scottish study [22], however, more than 50%
wished the genetic clinic to give post-test counseling
and support as well as test results. In the Dutch survey
[23] the proportion was 30%.
In this study we wanted to assess primary care physi-
cians' knowledge and attitudes towards breast-ovarian
cancer susceptibility testing as well as their perception
of their own role in the procedure.
Patients and methods
For this study a survey was conducted on all 400 general practitioners,
internists, obstetrician-gynecologists and oncologists in Geneva
county, Switzerland, who are in private practice and involved in direct
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patient care. Names were obtained through the 1997 directory of the
Geneva Medical Association, which includes the majority of the
physicians practising privately in Geneva. Data were collected by
means of a mailed questionnaire sent in September 1997. A covering
letter assured the participants of the confidentiality of the responses.
Respondents were given the opportunity to receive the conclusions of
the study if they wished. A stamped return envelope was included. If
the questionnaire was not returned within a month a second copy was
sent. It was decided that the survey would end two months after the
second mailing and questionnaires received later were not considered
for analysis.
Socio-demographic characteristics were collected (gender, age,
specialty, years in practice) and physicians were asked if they had a
personal familial history of breast and/or ovarian cancer in a first-
degree relative. Levels of knowledge were assessed by three questions.
The first two had multiple choice answers and inquired about the
prevalence of hereditary breast-ovarian cancer (HBOC) (less than
5%, 10%, 20%, 30%, 40%) and the penetrance of BRCA1/BRCA2
(20%, 40%, 60%, 80%, 100%). The last question was made up of five
items with three possible answers each (yes, no, do not know): earlier
age of onset, dominant inheritance pattern, transmission of suscepti-
bility only through females, characteristic histologic features, bilateral
primary breast cancers. One point was ascribed to each correct
answer, the maximum score being 7 points. Physicians' views on their
role and responsibility for the care of consultants were assessed by
three general questions adapted from the Scottish study of Mennie et
al. [22] about Huntington disease: 'do you as a general principle
approve of presymptomatic testing for individuals at high risk for
HBOC?', 'would you be agreeable in principle to referring a high risk
individual for genetic testing if she requested it?', 'would you feel that it
was your duty to inform a high risk individual that a genetic test is
available?'. Respondents were requested to list their objections if they
had given a negative answer or were unsure about any of the questions.
In addition they were asked more specific questions about the prelimi-
nary steps before offering a test, the delivering of test results and the
after care of individuals The issues to be addressed before genetic
susceptibility testing were chosen in accordance to the recommenda-
tions of the American Society of Clinical Oncology [13].
Data analysis
Quantitative variables are described by the mean ± standard deviation
(SD) They were compared by using (-tests and one-way or two-way
analyses of variance (ANOVA). When a significant difference was found
multiple comparisons according to Newtnan-Keuls were performed.
Qualitative variables were analysed using the x2 test or Fisher's exact
test, where appropriate.
Results
Two hundred fifty-nine (65%) of the four hundred ques-
tionnaires were returned, 75% of which were received
after the first mailing. Sixteen questionnaires (4%) were
blank: one physician preferred to abstain because none
of his patients was at high risk for breast and/or ovarian
cancer and three others wished to be sent the results
of the survey. Two hundred forty-three (61%) question-
naires were thus analysed. Not all respondents answered
every question.
The characteristics of the study population and the
mean knowledge score are listed in Table 1. The mean
age of the participants who returned questionnaires was
51 ± 9 years; 180 were men and 62 women (the sex of one
participant was unknown). Women were younger than
men (47 ± 9 vs. 52 ± 9 years; P < 0.001). Thirty-nine
Table 1. Characteristics and knowledge score of the study population.
Variable
Sex
Male
Female
Age (years)
Mean ± SD
Male
Female
Repartition
<45
46-53
3=54
Specialty
General practitioners
Internists
Obstetrician-gynecologists
Oncologists
Years in practice, mean ± SD
Breast and/or ovarian cancer
in a first-degree relative
Knowledge score (maximum:
7 points), mean ± SD
Number
(%)
180(74)
62 (26)
51 ±9
52 ±9
47 ±9
80
82
79
83 (34)
105(44)
50 (20)
5(2)
14.519
39(16)
2.31 1 6
Responses
n (%)
180(60)
62(76)a
83 (61)
105 (64)
50(67.5)
5 (45.5)
No responses
n (%)
121 (40)
20 (24)
53 (39)
58 (36)
24 (32.5)
6 (54.5)
a
 P = 0.008.
physicians (16%) had a personal familial history of
breast and/or ovarian cancer in a first-degree relative.
Participating physicians could be compared to the physi-
cians not returning the questionnaire as to two variables:
specialty and gender. Response rates were similar be-
tween the specialties. Female physicians however an-
swered more often than male (72% vs. 58%; P - 0.01).
The majority of the participants (n = 211; 87%)
approved of genetic susceptibility testing (Table 2). Thir-
teen percent (n = 32) disapproved of testing or were
unsure; this opinion was expressed more frequently
among women (23% vs. 10%; P - 0.01). Altogether
forty-nine respondents (20%) answered 'no' or 'unsure'
at least to one question. The most common reasons
given were 'it is not correct to do the test if there are no
approved strategies for the prevention and detection of
early breast cancer' (n - 39; 80%) and 'testing could do
more harm than good' (n = 34; 69%). For six partic-
ipants (12%) a positive result would imply more support
and follow-up care than they could supply. There was no
significant difference in the objections given by male and
female physicians.
For most physicians the tasks involved in the prelimi-
nary stage before performing the test belong to them
(from 81% to 89% 'yes') (Table 2). Two-thirds of re-
spondents (67%) would like to disclose the test results,
either alone (n = 131; 55%) or in collaboration with a
clinical genetics center (« = 29; 12%). Participants were
nearly unanimous (99%) in thinking the consultants'
long-term support was their responsibility. Fifteen of
them (6%) wished to work in collaboration with a
clinical genetics center.
Knowledge scores ranged from 0 to 6 points for a
maximum of 7 points with an average score of 2.3 ± 1.6.
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Table 2 Susceptibility testing for breast-ovarian cancer: primary care Table 3. Knowledge items.
pnyMcians auuuues anu pciccivcu i
Attitude
Approve of the principle of testing
Agree to refer a high risk patient
at her request
Think it his duty to inform a high
risk patient that a genetic test is
avai ab e
Role
Document a family history of
cancer
Recognize families for which
genetic testing is indicated
Provide counseling regarding
familial cancer risk
Provide options for prevention
and early detection of breast
cancer
Obtain informed consent before
testing
Yes
n (%)
211 (87)
238(98)
217(89)
Family
practitioner
n (%)
214(89)
207 (86)
195(81)
210(86)
210(87.5)
No
n (%)
7(3)
2(1)
4(2)
Genetic
center
n (%)
19(8)
11(5)
29(12)
15(6)
24(10)
Unsure
n (%)
25(10)
3d)
22(9)
Unsure
n
8
22
18
18
6
Item
Percentage of breast cancer
patients having an inherited
susceptibility to breast
cancer (answer: 10%)
Risk of developing a breast
cancer for carriers of a
predisposing mutation
(answer: 80%)
Features of breast cancer
associated with an inherited
susceptibility
Earlier age of onsetc
Dominant inheritance
pattern0
Transmission of suscepti-
bility only through
females
Characteristic histologic
features
Bilateral primary breast
c
cancers
Correct
answers
/O/"\a
n (%)
70(35)
36(19)
174(96)
44 (45)
33 (36)
71 (64)
122(80)
Incor-
rect
answers
n
131
156
7
53
59
40
30
'Do not
know'
answers
/o/ \ b
n (%)
30(13)
37(16)
52 (22)
128(57)
136(60)
118(51.5)
79 (34)
'Blank'
n
12
14
10
18
15
14
12
Both
n (%)
Deliver test results and give
post-test counseling
Provide follow-up support
131 (5 5) 79(33) 29 (12)
223(92.5) 3(1) 15(6)
Thus, respondents gave correct responses to about a
third (32%) of the items. Scores differed according to
specialties: on average oncologists numbered 4.8 points,
obstetrician-gynecologists 2.6, internists 2.2 and general
practitioners 1.9 (P - 0.0001). On multiple comparisons
oncologists scored higher than the other specialists
(P = 0.01 for internists and general practitioners;
P = 0.05 for obstetrician-gynecologists). Scores did not
differ with regard to sex, age and a personal familial
history of breast and/or ovarian cancer. As shown in
Table 3 the percentage of respondents answering cor-
rectly to individual knowledge items ranged from 19% to
96%. The abstention rate ('do not know') ranged from
13% to 60%. Nearly half the respondents (n = 99, 49%)
overrated the prevalence of HBOC; 81% (n = 156)
underrated the penetrance of BRCA1/BRCA2. More
than 50% did not know the inheritance pattern of the
mutations.
Discussion
Much attention has been directed towards women's
interest and knowledge about genetic testing for breast-
ovarian cancer susceptibility [8, 9, 24-31]. Despite a
a
 Percent relative to the total number of answers minus 'do not know'.
b
 Percent relative to the total number of answers.
0
 Correct answer.
widespread agreement about the prominent role family
physicians are likely to play in clinical practice, few data
are available about their attitudes towards BRCA1/
BRCA2 gene testing and how knowledgeable about
hereditary breast-ovarian cancer they actually are
[32-34]. In this survey we assessed primary health care
physicians likely to be directly involved in the testing
process. We asked specifically for their opinions about
the part they expect to play in both the pre- and post-test
procedure and evaluated how familiar they are with
HBOC and some of its specific features.
The satisfactory response rate suggests that primary
health care physicians feel concerned by the genetic
testing for susceptibility to breast-ovarian cancer. The
similar participation among specialties and the wide
range in the respondents' age show that this interest is
not restricted to a sub-group of practitioners. The choice
of pathology rather than genetic testing in itself most
probably accounts for the higher response rate among
women. No such difference was found in a previous
study [23] exploring general practitioners' attitudes to
presymptomatic testing for Huntington disease, a neuro-
degenerative disorder affecting both sexes, whereas
gender bias has been shown to affect the utilisation of
cancer screening tests [35].
The majority of respondents have a favourable opinion
about genetic testing. They approve of the principle of
testing and 98% would refer an individual at her request.
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Moreover they consider they have an active part to play
in all the stages of the testing procedure. They especially
affirm their responsibility as primary health care physi-
cians in the consultants' long-term support. Only six
respondents mentioned they might not be able to supply
the necessary follow-up care. Opinions about the delivery
of test results are divided. Half the respondents (55%)
would give the results themselves, 33% would like the
clinical genetics center to disclose the results and 12%
would collaborate with the clinical genetics center. This
can be explained by the technical aspect involved in the
communication of test results. Primary care physicians
may feel that it is beyond their scope to master the
complex and specific knowledge necessary to interpret
the results.
It is generally agreed that educational issues must be
addressed so that genetic counseling and testing can be
successfully integrated into clinical practice. Responses
to the questions of knowledge underscore the need for
educational programs. A high proportion of participants
cannot answer or give incorrect answers to the questions
(up to 60%, respectively, up to 81%). Oncologists, how-
ever, demonstrate a higher knowledge score than gyne-
cologists and general practitioners. It is in accordance
with previous observations that the greatest knowledge
about specific pathologies is found among physicians
caring for affected persons [14, 36, 37]. It can be inferred
that family practitioners will become more knowledge-
able not only through formal teaching but also by
encountering patients in their everyday practice.
Our findings suggest that primary care physicians are
favourable to genetic susceptibility testing for breast-
ovarian cancer and think it their responsibility to be in
charge of the consultants throughout the whole proce-
dure and for the ongoing medical care and support. To
help them perform the comprehensive tasks involved in
genetic counseling and testing, priority must be given to
targeted educational programs.
References
1. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate
for the breast and ovarian cancer susceptibility gene BRCA1.
Science 1994; 266: 66-71.
2. Wooster R, Neuhausen S, Mangion J et al. Localization of a
breast cancer susceptibility gene, BRCA2, to chromosome 13q
12-13. Science 1994; 265: 2088-90.
3. Wooster R, Bignell G, Lancaster J et al. Identification of the
breast cancer susceptibility gene BRCA2 Nature 1995; 378: 789-92.
4. American Society of Human Genetics. Statement of the American
Society of Human Genetics on genetic testing for breast and
ovarian cancer predisposition. Am J Hum Genet 1994; 55: i-iv.
5. Hoskins K, Stopfer J, Calzone K et al. Assessment and counseling
for women with a family history of breast cancer. JAMA 1995;
273: 577-85.
6. Weber R. Genetic testing: Are family physicians ready? Am Fam
Physician 1996: 53: 1976-8.
7. Cotton P. Prognosis, diagnosis, or who knows? Time to learn
what gene tests mean. JAMA 1995; 273: 93-5.
8. Lerman C, Daly M. Masny A. Balshem A. Attitudes about
genetic testing for breast-ovarian cancer susceptibility. J Clin
Oncol 1994; 12: 843-50.
9. Chaliki H, Loader S, Levenkron J et al. Women's receptivity to
testing for a genetic susceptibility to breast cancer. Am J Public
Health 1995; 85: 1133-5
10. Tambor ES, Rimer BK, Strigo TS. Genetic testing for breast
cancer susceptibility: Awareness and interest among women in
the general population. Am J Med Genet 1997; 68. 43-9.
11. Biesecker B, Boehnke M, Calzone K et al. Genetic counseling for
families with inherited susceptibility to breast and ovarian cancer.
JAMA 1993; 269: 1970-4.
12. Murday V. Genetic counselling in the cancer family clinic. Eur J
Cancer 1994; 30: 2012-5.
13. American Society of Clinical Oncology. Statement of the Ameri-
can Society of Clinical Oncology: Genetic testing for cancer
susceptibility. J Clin Oncology 1996; 14- 1730-6.
14. Hofman K, Tambor E, Chase G et al. Physicians' knowledge of
genetics and genetic tests. Acad Med 1993; 68: 625-32.
15. Fry A, Campbell H, Gudmundsdottir H et al. GPs' views on their
role in cancer genetics services and current practice. Fam Pract
1999; 16: 468-74.
16. Watson EK, Shickle D, Qureshi N et al. The 'new genetics' and
primary care: GPs' views on their role and their educational
needs. Fam Pract 1999; 16: 420-5
17. Giardiello F, Brensinger J, Petersen G et al. The use and interpre-
tation of commercial APC gene testing for familial adenomatous
polyposis. N Engl J Med 1997; 336: 823-7.
18. Geller G, Tambor E, Chase G, Holtzman N. Measuring physi-
cians' tolerance for ambiguity and its relationship to their
reported practices regarding genetic testing. Med Care 1993; 31.
989-1001.
19. Me Donald K., Doan B, Kelner M,Taylor K. A socio-behavioural
perspective on genetic testing and counselling for heritable breast,
ovarian and colon cancer. Can Med Assoc J 1996; 154 (4):
457-64.
20. Surh LC, Wright PG, Cappelli M et al. Delivery of molecular
genetic services within a health-care system: Time analysis of the
clinical workload. Am J Hum Genet 1995; 56: 760-8.
21. Worthen HG. Inherited cancer and the primary care physician:
Barriers and strategies. Cancer 1999; 86: 1763-8.
22. Mennie M, Holloway S, Brock D. Attitudes of general practi-
tioners to presymptomatic testing for Huntington's disease. J
Med Genet 1990; 27: 224-7.
23. Thomassen R, Tibben A et al. Attitudes of Dutch general practi-
tioners towards presymptomatic DNA-testing for Huntington's
disease. Clin Genet 1993; 43: 63-8.
24. Struewing JP, Lerman C, Kase RG et al. Anticipated uptake and
impact of genetic testing in hereditary breast and ovarian cancer
families. Cancer Epidemiol Biomark Prev 1995; 4( 2): 169-73.
25. Vennin P, Giard S, Julian-Reynier C et al. Attitudes of female
gynaecologists about screening and prevention of familial breast
and ovarian cancers in the North of France. Bull Cancer 1996; 83:
697-702.
26. Julian-Reynier C. Eisinger F, Vennin P et al. Attitudes towards
cancer predictive testing and transmission of information to the
family. J Med Genet 1996; 33: 731-6.
27. Lerman C, Narod S, Schulman K et al. BRCA1 testing in families
with hereditary breast-ovarian cancer, a prospective study of
patient decision making and outcomes. JAMA 1996; 275: 1885-92.
28. Hughes C, Gomez-Caminero A, Benkendorf J et al. Ethnic differ-
ences in knowledge and attitudes about BRCA1 testing in women
at increased risk. Patient Educ Couns 1997; 32: 51-62.
29. Durfy SJ, Bowen DJ, McTiernan A et al. Attitudes and interest in
genetic testing for breast and ovarian cancer susceptibility in
diverse groups of women in western Washington. Cancer Epide-
miol Biomarkers Prev 1999; 8 (4): 369-75.
30. Cappelli M. Surh L. Humphreys L et al. Psychological and social
determinants of women's decisions to undergo genetic counseling
and testing for breast cancer. Clin Genet 1999; 55: 419-30.
31. Bluman LG, Rimer BK, Berry DA et al. Attitudes, knowledge,
1135
and risk perceptions of women with breast and/or ovarian cancer
considering testing for BRCA1 and BRCA2. J Clin Oncol 1999; 17
(3): 1040-6.
32. Rowley PT, Loader S. Attitudes of obstetrician-gynecologists
toward DNA testing for a genetic susceptibility to breast cancer.
Obstet Gynecol 1996; 88: 611-5.
33. O'Malley MS, Lkabunde CN, McKinley ED, Newman B. Should
we test women for inherited susceptibility to breast cancer? What
do NC primary care physicians think. N C Med J 1997; 58 (3):
176-80.
34. Alexakos FM. Rhode Island primary care physicians' attitudes
toward genetic testing for breast cancer. Med Health R 11999; 82
(5): 171.
35. Franks P, Clancy C. Physician gender bias in clinical decision-
making: Screening for cancer in primary care. Med Care 1993; 31:
213-8.
36. Firth HV, Lindenbaum RH. UK clinicians' knowledge of and
attitudes to the prenatal diagnosis of single gene disorders. J Med
Genet 1992; 29: 20-3.
37. Hunter A, Wright P, Cappelli M et al. Physician knowledge and
attitudes towards molecular genetic (DNA) testing of their
patients. Clin Genet 1998; 53: 447-55.
Received 5 April 2000; accepted 13 June 2000.
Correspondence to:
Dr M. Escher
Geneva University Hospital
rue Micheh-du-Crest 24
1211 Geneva 14
Switzerland
E-mail: monica.escherimhof@hcuge.ch

